Speaker: W. Frank An, PhD.

Sr. Director of Antibody Therapeutics, Biocytogen Institute for Therapeutic Innovations, Biocytogen Pharmaceuticals

About the webinar:

Bispecific ADCs are a growing trend in the ADC field, offering improved efficacy and safety for the treatment of heterogeneous solid tumors. Designing bsADCs requires careful selection of targets, and is not without challenges, including the ability to efficiently screen and assemble bsAbs for further conjugation. To facilitate bsADC development, Biocytogen established a bsADC platform, which harnesses:

• a fully human common light chain antibody discovery platform (RenLite),
• an antibody library targeting tumor-associated antigens (TAAs), and
• a novel proprietary linker/payload system, BLD1102, consisting of a super hydrophilic linker and a potent topoisomerase I inhibitor (TOP1i) payload.

In this webinar, Dr. W. Frank An discussed the current landscape of bsADCs as a novel therapeutic modality, and provided an introduction to Biocytogen’s bsADC platform, highlighting the recent progress of several of the company’s bsADC assets.